CN1923182A - Lacidipine tablets disintegrating in oral cavity and process for producing same - Google Patents
Lacidipine tablets disintegrating in oral cavity and process for producing same Download PDFInfo
- Publication number
- CN1923182A CN1923182A CN 200610095133 CN200610095133A CN1923182A CN 1923182 A CN1923182 A CN 1923182A CN 200610095133 CN200610095133 CN 200610095133 CN 200610095133 A CN200610095133 A CN 200610095133A CN 1923182 A CN1923182 A CN 1923182A
- Authority
- CN
- China
- Prior art keywords
- lacidipine
- oral cavity
- mix homogeneously
- mixture
- crospolyvinylpyrrolidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a Laxi mouse disintegration tablet for treating cardiovascular disease and relative production. Wherein, said drug is mouse disintegration tablet, formed by Laxi, stuff, disintegrator, corrective, lubricant, and flow agent, via wet method or compression, while its disintegration time is 30-55s, and it uses deionized water as exsolution medium, while the exsolution rate at 30mins is 70-80%. The invention can be quickly absorbed, with simple process.
Description
Technical field
The present invention relates to a kind of pharmaceutical preparation for the treatment of cardiovascular disease and preparation method thereof, particularly Lacidipine tablets disintegrating in oral cavity and preparation method thereof.
Technical background
Lacidipine (Lacidipine) is a kind of novel dihydropyridine type calcium antagonists, its chemical name is: (E)-4-[2-[3-(the carboxylic tert-butyl group)-3-oxo-1-acrylic] phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridine-dicarboxylate, molecular formula: C26H33NO6, molecular weight: 455.59, structural formula is:
Lacidipine belongs to the long-acting dihydropyridine calcium ion antagonist of the third generation (CCB), the tool high selectivity acts on the calcium channel of smooth muscle, main expansion peripheral arterial, reduce Peripheral resistance, hypotensive effect is strong and lasting, the clinical treatment hypertension that is mainly used in, be characterized in evident in efficacy, onset is mild, and dosage is few, lasting medicine (only obey once by every day, 2-6mg), untoward reaction is few, and it has overcome effectively, and like product was short action time in the past, the blood pressure lowering instability, shortcomings such as untoward reaction is many, and extra diuresis and antioxidation are arranged.Just because of lacidipine has these unique pharmacology, drug action, now, become one of hypertensive choice drug of treatment by increasing hyperpietic's approval.
In addition, lacidipine can also be treated angina pectoris, has potential antiatherogenic effect, is one of best medicine of curative effect in the existing antihypertensive drug.The ordinary tablet dosage form that this medicine is only arranged on the medical market at present.
The conventional tablet disintegrate is slower, bioavailability is lower, need finish drug administration process by drinking-water and by swallowing act, the comparatively difficulty because part patient (as old people and child) swallows, and medication is subjected to the restriction of (as lacking drinking water) of some specific conditions, thereby promoting the use of to a certain extent of tablet is restricted.So existing lacidipine conventional tablet can not satisfy all patients' medication needs.
Oral cavity disintegration tablet (Orally disintegrating tablets) is the novel pharmaceutical formulation that occurs in recent years, this dosage form need not water (or only needing low amounts of water) and also need not to chew, medicine places on the tongue, after meeting rapid dissolving of saliva or disintegrate, borrow swallowing act to go into the stomach onset, so be particularly suitable for the patient of some old peoples, child and dysphagia, and the patient under the anhydrous condition takes, and it has the characteristics rapid-action, that bioavailability is high.
Summary of the invention
The purpose of this invention is to provide simple, the taking convenience of a kind of preparation technology, the Lacidipine tablets disintegrating in oral cavity that disintegrate is rapid and bioavailability is high makes the patient of some old peoples, child and dysphagia can take the lacidipine medicine easily.
Another object of the present invention provides the preparation method of Lacidipine tablets disintegrating in oral cavity.
Lacidipine tablets disintegrating in oral cavity provided by the invention, its type agent is an oral cavity disintegration tablet, its prescription is composed as follows by weight percentage:
Lacidipine 4～8%,
Polyvinylpyrrolidone 4～6%
Lactose or mannitol or its mixture 40～67%
Microcrystalline Cellulose 15～25%
Crospolyvinylpyrrolidone 5～12%
Low-substituted hydroxypropyl cellulose 3～6%
Aspartame 0.25～0.5%
Herba Menthae essence 0.25～0.5%
Magnesium stearate 0.5～2%
Silicon dioxide 0.5～2%.
Wherein polyvinylpyrrolidone is a binding agent, lactose, mannitol are filler, and microcrystalline Cellulose, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose are disintegrating agent, and aspartame, Herba Menthae essence are correctives, magnesium stearate is a lubricant, and silicon dioxide is fluidizer.
This prescription is particularly suitable for wet granulation technology, and its preparation method is:
It is standby that the each component pulverize separately is crossed 100 mesh sieves in will filling a prescription; Lacidipine and polyvinylpyrrolidone are dissolved in the dehydrated alcohol, get the alcoholic solution of lacidipine; With lactose or mannitol or its mixture, and the microcrystalline Cellulose of formula ratio 50-80%, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose mix homogeneously, get mixture A, under stirring condition, above-mentioned lacidipine alcoholic solution is added among the mixture A, granulation, drying get dried particles; The microcrystalline Cellulose, crospolyvinylpyrrolidone, the low-substituted hydroxypropyl cellulose that in the gained dried particles, add surplus in the prescription, and aspartame, Herba Menthae essence, magnesium stearate, silicon dioxide, granulate, mix homogeneously; Granule tabletting with mix homogeneously promptly gets the lacidipine oral cavity disintegration tablet.
Lacidipine is a poorly water soluble drugs, and oral administration biaavailability is low.This technical scheme is with lacidipine and hydrophilic polymer---polyvinylpyrrolidone is dissolved in the ethanol jointly, whole filleies and part disintegrating agent mix homogeneously in will filling a prescription simultaneously, then under high-speed stirred with the ethanol liquid high degree of dispersion of lacidipine at these above blended adjuvant, thereby increase the surface area of lacidipine significantly; In prescription, use an amount of disintegrating agent simultaneously again, the two collaborative dissolution that just can increase substantially lacidipine.
Lacidipine tablets disintegrating in oral cavity provided by the invention, its type agent is an oral cavity disintegration tablet, its prescription is composed as follows by weight percentage:
Lacidipine 4～8%,
Lactose or sucrose or mannitol or its mixture 70～80%
Carboxymethyl starch sodium 4～8%
Microcrystalline Cellulose 5～15%
Crospolyvinylpyrrolidone 4～9%
Aspartame 0.25～0.5%
Herba Menthae essence 0.25～0.5%
Magnesium stearate 0.5～2%
Silica 1 .0～2%.
Wherein lactose, mannitol, sucrose are filler, and carboxymethyl starch sodium, microcrystalline Cellulose, crospolyvinylpyrrolidone are that disintegrating agent, aspartame, Herba Menthae essence are correctives, and magnesium stearate is a lubricant, and silicon dioxide is fluidizer.
This prescription is particularly suitable for direct compression technology, and its preparation method is:
Lacidipine and lactose or sucrose or mannitol or its mixture and carboxymethyl starch sodium mixed and make micronization processes, get the mixture of powders of mix homogeneously, to wherein adding microcrystalline Cellulose, crospolyvinylpyrrolidone, aspartame, Herba Menthae essence, magnesium stearate, silicon dioxide, and mix homogeneously; With the pressed powder of mix homogeneously, promptly get the lacidipine oral cavity disintegration tablet.
Lacidipine is a poorly water soluble drugs, and oral administration biaavailability is low.The common micronization processes of---lactose, mannitol, sucrose and disintegrating agent---carboxymethyl starch sodium that this technical scheme is with lacidipine and water soluble adjuvant, thereby reach the particle diameter that reduces lacidipine, increase surface area, also avoided simple employing lacidipine micronization simultaneously and make the problem of particle accumulation; Add disintegrating agent an amount of in the prescription, the two collaborative dissolution that just can increase substantially lacidipine.
The present invention selects good filler and disintegrating agent for use, and the oral cavity disintegration tablet that adopts appropriate preparation process to make, disintegrate becomes fine powder rapidly behind the tablet inlet, its disintegration time is 30～55 seconds, thereby make the large-area gastrointestinal tract that is distributed in the oral back of lacidipine, to reach rapid absorption onset and to improve its bioavailability, with the deionized water dissolution medium, stripping in 30 minutes is 70～80%.
Because the disintegrate rapidly of this oral cavity disintegration tablet, so taking convenience, its good mouthfeel is for dysphagia or inconvenient the taking of patient of fetching water provide convenience.
And preparation technology is simple for this oral cavity disintegration tablet, easily realizes suitability for industrialized production, only adopts the pharmaceutical manufacturing equipment of conventional conventional tablet to get final product.
The specific embodiment
Embodiment one:
This lacidipine oral cavity disintegration tablet is formulated by following component:
Lacidipine 4g
Polyvinylpyrrolidone 6g
Lactose 45g
Mannitol 15g
Microcrystalline Cellulose 15g
Crospolyvinylpyrrolidone 8.5g
Low-substituted hydroxypropyl cellulose 4.5g
Aspartame 0.25g
Herba Menthae essence 0.25g
Magnesium stearate 0.5g
Silica 1 .0g
Its preparation method is:
It is standby that the each component pulverize separately is crossed 100 mesh sieves in will filling a prescription; Lacidipine and polyvinylpyrrolidone are dissolved in the dehydrated alcohol, get the alcoholic solution of lacidipine; With lactose and mannitol, and microcrystalline Cellulose 10.5g, crospolyvinylpyrrolidone 4.3g, low-substituted hydroxypropyl cellulose 2.3g mix homogeneously, get mixture A, under the high-speed stirred condition, above-mentioned lacidipine alcoholic solution is slowly added mixture A camber dispersion and granulation, drying, dried particles; The microcrystalline Cellulose, crospolyvinylpyrrolidone, the low-substituted hydroxypropyl cellulose that in the gained dried particles, add surplus in the prescription, and aspartame, Herba Menthae essence, magnesium stearate, silicon dioxide, granulate, mix homogeneously; The granule of mix homogeneously is adopted the tablet machine tabletting of making conventional tablet, form sheet and heavily be 1000 of the lacidipine oral cavity disintegration tablets of 100mg.
Result of the test:
Tablet hardness: 2.0～3.0kg
Disintegration time: 30～55 seconds
Dissolution: with the deionized water is dissolution medium, and stripping in 30 minutes is 80%
Intraoral disintegration time and mouthfeel: disintegrate in 45 seconds, no grittiness, no foreign body sensation does not have bad taste.
Embodiment two:
This lacidipine oral cavity disintegration tablet is formulated by following component:
Lacidipine 6g
Polyvinylpyrrolidone 6g
Lactose 50g
Microcrystalline Cellulose 20g
Crospolyvinylpyrrolidone 9.3g
Low-substituted hydroxypropyl cellulose 6g
Aspartame 0.35g
Herba Menthae essence 0.35g
Magnesium stearate 1g
Silica 1 g
Its preparation method is:
It is standby that the each component pulverize separately is crossed 100 mesh sieves in will filling a prescription; Lacidipine and polyvinylpyrrolidone are dissolved in the dehydrated alcohol, get the alcoholic solution of lacidipine; With lactose, and microcrystalline Cellulose 10g, crospolyvinylpyrrolidone 4.7g, low-substituted hydroxypropyl cellulose 3g mix homogeneously, mixture A, under the high-speed stirred condition, above-mentioned lacidipine alcoholic solution is slowly added mixture A camber dispersion and granulation, drying, dried particles; The microcrystalline Cellulose, crospolyvinylpyrrolidone, the low-substituted hydroxypropyl cellulose that in the gained dried particles, add surplus in the prescription, and aspartame, Herba Menthae essence, magnesium stearate, silicon dioxide, granulate, mix homogeneously; The granule of mix homogeneously is adopted the tablet machine tabletting of making conventional tablet, form sheet and heavily be 1000 of the lacidipine oral cavity disintegration tablets of 100mg.
Result of the test:
Tablet hardness: 1.5-3.0kg
Disintegration time: 30-50 second
Dissolution: with the deionized water is dissolution medium, and stripping in 30 minutes is 75%
Intraoral disintegration time and mouthfeel: disintegrate in 40 seconds, no grittiness, no foreign body sensation does not have bad taste.
Embodiment three:
This lacidipine oral cavity disintegration tablet is formulated by following component:
Lacidipine 8g
Polyvinylpyrrolidone 5g
Mannitol 51g
Microcrystalline Cellulose 20g
Crospolyvinylpyrrolidone 8g
Low-substituted hydroxypropyl cellulose 3g
Aspartame 0.5g
Herba Menthae essence 0.5g
Magnesium stearate 2g
Silicon dioxide 2g
Its preparation method is:
It is standby that the each component pulverize separately is crossed 100 mesh sieves in will filling a prescription; Lacidipine and polyvinylpyrrolidone are dissolved in the dehydrated alcohol, get the alcoholic solution of lacidipine; With mannitol, and microcrystalline Cellulose 10g, crospolyvinylpyrrolidone 4g, low-substituted hydroxypropyl cellulose 2.4g mix homogeneously, get mixture A, under the high-speed stirred condition, above-mentioned lacidipine alcoholic solution is slowly added mixture A camber dispersion and granulation, drying, dried particles; The microcrystalline Cellulose, crospolyvinylpyrrolidone, the low-substituted hydroxypropyl cellulose that in the gained dried particles, add surplus in the prescription, and aspartame, Herba Menthae essence, magnesium stearate, silicon dioxide, granulate, mix homogeneously; The granule of mix homogeneously is adopted the tablet machine tabletting of making conventional tablet, form sheet and heavily be 1000 of the lacidipine oral cavity disintegration tablets of 100mg.
Result of the test:
Tablet hardness: 1.5-3.0kg
Disintegration time: 30-55 second
Dissolution: with the deionized water is dissolution medium, and stripping in 30 minutes is 70%
Intraoral disintegration time and mouthfeel: disintegrate in 40 seconds, no grittiness, no foreign body sensation does not have bad taste.
Embodiment four:
This lacidipine oral cavity disintegration tablet is formulated by following component:
Lacidipine 6g
Lactose 52g
Mannitol 10g
Sucrose 8g
Carboxymethyl starch sodium 6g
Microcrystalline Cellulose 7g
Crospolyvinylpyrrolidone 9g
Aspartame 0.5g
Herba Menthae essence 0.5g
Magnesium stearate 0.5g
Silicon dioxide 0.5g
Its preparation method is:
Lacidipine mixed with lactose, sucrose, mannitol and carboxymethyl starch sodium and make micronization processes, get the mixture of powders of mix homogeneously, to wherein adding microcrystalline Cellulose, crospolyvinylpyrrolidone, aspartame, Herba Menthae essence, magnesium stearate, silicon dioxide, and mix homogeneously; The powder of mix homogeneously is adopted the tablet machine tabletting of making conventional tablet, form sheet and heavily be 1000 of the lacidipine oral cavity disintegration tablets of 100mg.
Result of the test:
Tablet hardness: 1.5-3.0kg
Disintegration time: 30-50 second
Dissolution: with the deionized water is dissolution medium, and stripping in 30 minutes is 72%
Intraoral disintegration time and mouthfeel: disintegrate in 35 seconds, no grittiness, no foreign body sensation does not have bad taste.
Embodiment five:
This lacidipine oral cavity disintegration tablet is formulated by following component:
Lacidipine 4g
Lactose 50g
Sucrose 20g
Microcrystalline Cellulose 8.8g
Carboxymethyl starch sodium 7g
Crospolyvinylpyrrolidone 6.5g
Aspartame 0.35g
Herba Menthae essence 0.35g
Magnesium stearate 1.5g
Silica 1 .5g
Its preparation method is:
Lacidipine mixed with lactose, sucrose and carboxymethyl starch sodium and make micronization processes, get the mixture of powders of mix homogeneously, to wherein adding microcrystalline Cellulose, crospolyvinylpyrrolidone, aspartame, Herba Menthae essence, magnesium stearate, silicon dioxide, and mix homogeneously; The powder of mix homogeneously is adopted the tablet machine tabletting of making conventional tablet, form sheet and heavily be 1000 of the lacidipine oral cavity disintegration tablets of 100mg.
Result of the test:
Tablet hardness: 2.0-3.0kg
Disintegration time: 30-50 second
Dissolution: with the deionized water is dissolution medium, and stripping in 30 minutes is 73.0%
Intraoral disintegration time and mouthfeel: disintegrate in 35 seconds, no grittiness, no foreign body sensation does not have bad taste.
Embodiment six:
This lacidipine oral cavity disintegration tablet is formulated by following component:
Lacidipine 8g
Lactose 77g
Microcrystalline Cellulose 5g
Carboxymethyl starch sodium 4g
Crospolyvinylpyrrolidone 4g
Aspartame 0.25g
Herba Menthae essence 0.25g
Magnesium stearate 0.5g
Silica 1 g
Its preparation method is:
Lacidipine mixed with lactose, carboxymethyl starch sodium and make micronization processes, get the mixture of powders of mix homogeneously, to wherein adding microcrystalline Cellulose, crospolyvinylpyrrolidone, aspartame, Herba Menthae essence, magnesium stearate, silicon dioxide, and mix homogeneously; The powder of mix homogeneously is adopted the tablet machine tabletting of making conventional tablet, form sheet and heavily be 1000 of the lacidipine oral cavity disintegration tablets of 100mg.
Result of the test:
Tablet hardness: 2.0-3.0kg
Disintegration time: 30-50 second
Dissolution: with the deionized water is dissolution medium, and stripping in 30 minutes is 74.5%
Intraoral disintegration time and mouthfeel: disintegrate in 35 seconds, no grittiness, no foreign body sensation does not have bad taste.
Embodiment seven:
This lacidipine oral cavity disintegration tablet is formulated by following component:
Lacidipine 8g
Sucrose 68g
Microcrystalline Cellulose 12g
Carboxymethyl starch sodium 4g
Crospolyvinylpyrrolidone 4g
Aspartame 0.25g
Herba Menthae essence 0.25g
Magnesium stearate 1.5g
Silicon dioxide 2g
Its preparation method is:
Lacidipine mixed with sucrose, carboxymethyl starch sodium and make micronization processes, get the mixture of powders of mix homogeneously, to wherein adding microcrystalline Cellulose, crospolyvinylpyrrolidone, aspartame, Herba Menthae essence, magnesium stearate, silicon dioxide, and mix homogeneously; The powder of mix homogeneously is adopted the tablet machine tabletting of making conventional tablet, form sheet and heavily be 1000 of the lacidipine oral cavity disintegration tablets of 100mg.
Result of the test:
Tablet hardness: 1.5-3.0kg
Disintegration time: 30-50 second
Dissolution: with the deionized water is dissolution medium, and stripping in 30 minutes is 72%
Intraoral disintegration time and mouthfeel: disintegrate in 35 seconds, no grittiness, no foreign body sensation does not have bad taste.
Embodiment eight:
This lacidipine oral cavity disintegration tablet is formulated by following component:
Lacidipine 5g
Mannitol 70g
Microcrystalline Cellulose 15g
Carboxymethyl starch sodium 4g
Crospolyvinylpyrrolidone 4g
Aspartame 0.25g
Herba Menthae essence 0.25g
Magnesium stearate 0.5g
Silica 1 g
Its preparation method is:
Lacidipine mixed with mannitol, carboxymethyl starch sodium and make micronization processes, get the mixture of powders of mix homogeneously, to wherein adding microcrystalline Cellulose, crospolyvinylpyrrolidone, aspartame, Herba Menthae essence, magnesium stearate, silicon dioxide, and mix homogeneously; The powder of mix homogeneously is adopted the tablet machine tabletting of making conventional tablet, form sheet and heavily be 1000 of the lacidipine oral cavity disintegration tablets of 100mg.
Result of the test:
Tablet hardness: 1.5-3.0kg
Disintegration time: 30-50 second
Dissolution: with the deionized water is dissolution medium, and stripping in 30 minutes is 70%
Intraoral disintegration time and mouthfeel: disintegrate in 35 seconds, no grittiness, no foreign body sensation does not have bad taste.
Embodiment nine:
This lacidipine oral cavity disintegration tablet is formulated by following component:
Lacidipine 6g
Mannitol 55g
Sucrose 20g
Carboxymethyl starch sodium 6g
Microcrystalline Cellulose 6g
Crospolyvinylpyrrolidone 4g
Aspartame 0.5g
Herba Menthae essence 0.5g
Magnesium stearate 1g
Silica 1 g
Its preparation method is:
Lacidipine mixed with sucrose, mannitol and carboxymethyl starch sodium and make micronization processes, get the mixture of powders of mix homogeneously, to wherein adding microcrystalline Cellulose, crospolyvinylpyrrolidone, aspartame, Herba Menthae essence, magnesium stearate, silicon dioxide, and mix homogeneously; The powder of mix homogeneously is adopted the tablet machine tabletting of making conventional tablet, form sheet and heavily be 1000 of the lacidipine oral cavity disintegration tablets of 100mg.
Result of the test:
Tablet hardness: 1.5-3.0kg
Disintegration time: 30-50 second
Dissolution: with the deionized water is dissolution medium, and stripping in 30 minutes is 71.5%
Intraoral disintegration time and mouthfeel: disintegrate in 35 seconds, no grittiness, no foreign body sensation does not have bad taste.
Claims (4)
1, a kind of Lacidipine tablets disintegrating in oral cavity is characterized in that: the type agent of said preparation is an oral cavity disintegration tablet, and its prescription is composed as follows by weight percentage:
Lacidipine 4～8%,
Polyvinylpyrrolidone 4～6%
Lactose or mannitol or its mixture 40～67%
Microcrystalline Cellulose 15～25%
Crospolyvinylpyrrolidone 5～12%
Low-substituted hydroxypropyl cellulose 3～6%
Aspartame 0.25～0.5%
Herba Menthae essence 0.25～0.5%
Magnesium stearate 0.5～2%
Silicon dioxide 0.5～2%.
2, the preparation method of Lacidipine tablets disintegrating in oral cavity according to claim 1 is characterized in that: it is standby that the each component pulverize separately is crossed 100 mesh sieves in will filling a prescription; Lacidipine and polyvinylpyrrolidone are dissolved in the dehydrated alcohol, get the alcoholic solution of lacidipine; With lactose or mannitol or its mixture, and the microcrystalline Cellulose of formula ratio 50-80%, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose mix homogeneously, get mixture A, under stirring condition, above-mentioned lacidipine alcoholic solution is added among the mixture A, granulation, drying get dried particles; The microcrystalline Cellulose, crospolyvinylpyrrolidone, the low-substituted hydroxypropyl cellulose that in the gained dried particles, add surplus in the prescription, and aspartame, Herba Menthae essence, magnesium stearate, silicon dioxide, granulate, mix homogeneously; Granule tabletting with mix homogeneously promptly gets the lacidipine oral cavity disintegration tablet.
3, a kind of Lacidipine tablets disintegrating in oral cavity is characterized in that: the type agent of said preparation is an oral cavity disintegration tablet, and its prescription is composed as follows by weight percentage:
Lacidipine 4～8%,
Lactose or sucrose or mannitol or its mixture 70～80%
Carboxymethyl starch sodium 4～8%
Microcrystalline Cellulose 5～15%
Crospolyvinylpyrrolidone 4～9%
Aspartame 0.25～0.5%
Herba Menthae essence 0.25～0.5%
Magnesium stearate 0.5～2%
Silica 1 .0～2%.
4, the preparation method of Lacidipine tablets disintegrating in oral cavity according to claim 3, it is characterized in that: lacidipine and lactose or sucrose or mannitol or its mixture and carboxymethyl starch sodium are mixed and make micronization processes, get the mixture of powders of mix homogeneously, to wherein adding microcrystalline Cellulose, crospolyvinylpyrrolidone, aspartame, Herba Menthae essence, magnesium stearate, silicon dioxide, and mix homogeneously; With the pressed powder of mix homogeneously, promptly get the lacidipine oral cavity disintegration tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610095133 CN1923182A (en) | 2006-09-16 | 2006-09-16 | Lacidipine tablets disintegrating in oral cavity and process for producing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610095133 CN1923182A (en) | 2006-09-16 | 2006-09-16 | Lacidipine tablets disintegrating in oral cavity and process for producing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1923182A true CN1923182A (en) | 2007-03-07 |
Family
ID=37816126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610095133 Pending CN1923182A (en) | 2006-09-16 | 2006-09-16 | Lacidipine tablets disintegrating in oral cavity and process for producing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1923182A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102133203A (en) * | 2011-03-15 | 2011-07-27 | 佟兵 | Lacidipine dispersible tablet and preparation method thereof |
| CN102198107A (en) * | 2011-05-18 | 2011-09-28 | 浙江贝得药业有限公司 | Lacidipine dispersible tablets and preparation method thereof |
| CN102499907A (en) * | 2011-11-02 | 2012-06-20 | 华裕(无锡)制药有限公司 | Orally disintegrating tablet composition |
-
2006
- 2006-09-16 CN CN 200610095133 patent/CN1923182A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102133203A (en) * | 2011-03-15 | 2011-07-27 | 佟兵 | Lacidipine dispersible tablet and preparation method thereof |
| CN102133203B (en) * | 2011-03-15 | 2012-07-11 | 佟兵 | Lacidipine dispersible tablet and preparation method thereof |
| CN102198107A (en) * | 2011-05-18 | 2011-09-28 | 浙江贝得药业有限公司 | Lacidipine dispersible tablets and preparation method thereof |
| CN102198107B (en) * | 2011-05-18 | 2012-11-21 | 浙江贝得药业有限公司 | Lacidipine dispersible tablets and preparation method thereof |
| CN102499907A (en) * | 2011-11-02 | 2012-06-20 | 华裕(无锡)制药有限公司 | Orally disintegrating tablet composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1182841C (en) | New pharmaceutical formulation and preparation process | |
| CN1809341A (en) | Multilayer orodispersible tablet | |
| CN101066251A (en) | Dispersed tablet of proton pump inhibitor | |
| CN1302605A (en) | Controlled releasing oral medicine composition | |
| CN101036633A (en) | Enteric coated omeprazole pellets capsule and the preparing method thereof | |
| CN1284866A (en) | Oral pharmaceutical extended release dosage form | |
| CN1215338A (en) | Pharmaceutical combination containing a compound having angiotensin II and antagonisti activity | |
| CN101066279A (en) | Chewing tablet of proton pump inhibitor | |
| CN1515257A (en) | Paroxetine control-released composite | |
| CN1929821A (en) | Pharmaceutical composition comprising pimobendan | |
| CN1527700A (en) | Compaction process for manufacture of sodium phenytoin dosage form | |
| CN101028254A (en) | Sustaining agent of Duosuo theosine and its preparation | |
| CN1923182A (en) | Lacidipine tablets disintegrating in oral cavity and process for producing same | |
| CN1631247A (en) | Health food with hypoxia preventing and anti-fatigue function and preparation technique thereof | |
| CN1868463A (en) | Slow-release prepn. contg. alpha-lipoic acid or its derivatives, and preparing method therefor | |
| CN1269480C (en) | Orally disintegrating tablet of loratadine and its preparation method | |
| CN1857288A (en) | Slow released compound preparation of glycyrrhizic acid and glycyrrhizinate and its preparing process | |
| CN1765362A (en) | Composition containing amlodipine and angiotensin II receptor inhibitor | |
| CN1823805A (en) | Ground erythromycin enteric micropill and its preparation method | |
| CN101028518A (en) | Medicinal composition containing silver ester medicine and ibobulodine | |
| CN1279920C (en) | Slow release preparation of diammonium glycyrrhizate | |
| CN1891218A (en) | Ranolazine hydrochloride slow-release preparation and its preparing method | |
| CN1745797A (en) | Medicine for treating menstrual irregularities and menalgia | |
| CN1723964A (en) | Medicine for treating cough and chronic bronchitis | |
| CN1631358A (en) | Compound pseudoephedrine hydrochloric acid containing powder for treating cold, its prescription and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |